Tuberculosis (TB) is the most common co-infection during Human Immunodeficiency Virus-1 (HIV) infection worldwide, and is associated with significant HIV-related morbidity and mortality. Unlike other HIV associated opportunistic infections (OI), TB occurs throughout the course of HIV infection, and its impact on viral activity is not reversible by anti-TB treatment alone. Studies by HL-51636 have examined the basis of HIV expansion systemically and at local sites of dual HIV/TB infection. At these sites MTB induces HIV replication in both macrophages and T-cells, and this HIV compartment contributes to systemic HIV load and heterogeneity. Cytokines/chemokine and the cellular composition at sites of dual HIV/MTB infection are important factors in the impact of TB on HIV disease. The milieu at pleural sites of HIV/TB infection is characterized by excessive TGF-2, IL-6, M-CSF-1, and MCP-1 activity in addition to a TH1 profile, and a massive expansion of memory and regulatory T-cells (T-reg). PFMC T-reg have survival advantage over non T-reg, suppress effector T-cell immune responses to HIV, and are particularly poised to productive HIV infection. Further, upon MTB stimulation macrophages both transmit HIV infection to, trans-activate HIV production in CD4 T-cells, and support T-reg expansion. Recent studies have identified three compounds that potentially target the excessive cytokine/chemokine profile of HIV/TB, and therefore may be useful as short-term adjuncts to anti-TB treatment. These include;1. Derivatives of erythromycin, some of which may be useful in MDR TB, 2. an inhibitor of CDK9 (of P-TEFb), Indirubicin Monoxime, and 3. the anti-neoplastic agent Imatinib, which counter-acts the pro-survival factor M-CSF, and may be conducive to apoptosis of HIV-infected macrophages. We hypothesize that the cellular composition and cytokine/chemokine milieu at sites of HIV/TB co- infection is conducive to increased HIV replication and spread to CD4 T-cells by macrophages and T-reg. These mononuclear cell subsets undermine anti-HIV T-cell immune responses and contribute to HIV reservoirs. Modulation of the interface of HIV and host molecules by novel adjunctive anti-HIV therapies may allow control of the co-pathogenesis of HIV and MTB infection at sites of dual infection.
The Specific Aims are: 1. To determine the mechanism(s) of enhanced HIV infection of MTB-specific CD4+ T cells by macrophages and DC in PFMC from HIV/TB dually infected patients, and to examine the role of macrophages and DC in expansion of T-reg. 2. To determine the role of T-reg expanded at pleural sites of HIV/TB infection on immune responses to HIV, and their contribution to viral dynamics including productive infection and latency during HIV/TB. 3. To determine whether specific adjunctive therapies such as EM-703, IM, or Imatinib that have been shown to have anti-HIV activity in macrophages and/or inhibit T-reg are useful in HIV/TB patients with pleural TB.
TB is the most common co-infection during HIV infection worldwide, and is associated with significant HIV-related morbidity and mortality. This research will identify mechanisms by which TB impacts HIV that may be modulated by adjunctive therapies.
|Mayanja-Kizza, H; Wu, M; Aung, H et al. (2009) The interaction of monocyte chemoattractant protein-1 and tumour necrosis factor-alpha in Mycobacterium tuberculosis-induced HIV-1 replication at sites of active tuberculosis. Scand J Immunol 69:516-20|
|Toossi, Zahra; Mayanja-Kizza, Harriet; Lawn, Stephen D et al. (2007) Dynamic variation in the cellular origin of HIV type 1 during treatment of tuberculosis in dually infected subjects. AIDS Res Hum Retroviruses 23:93-100|
|Kizza, Harriet Mayanja; Rodriguez, Benigno; Quinones-Mateu, Miguel et al. (2005) Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. Clin Diagn Lab Immunol 12:1298-304|
|Aung, H; Wu, M; Johnson, J L et al. (2005) Bioactivation of latent transforming growth factor beta1 by Mycobacterium tuberculosis in human mononuclear phagocytes. Scand J Immunol 61:558-65|
|Toossi, Z; Mayanja-Kizza, H; Kanost, A et al. (2004) Protective responses in tuberculosis: induction of genes for interferon-gamma and cytotoxicity by Mycobacterium tuberculosis and during human tuberculosis. Scand J Immunol 60:299-306|
|Toossi, Zahra; Wu, Mianda; Islam, Najmul et al. (2004) Transactivation of human immunodeficiency virus-1 in T-cells by Mycobacterium tuberculosis-infected mononuclear phagocytes. J Lab Clin Med 144:108-15|
|Collins, Kalonji R; Quinones-Mateu, Miguel E; Toossi, Zahra et al. (2002) Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 4:165-76|
|Mayanja-Kizza, H; Wajja, A; Wu, M et al. (2001) Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. J Infect Dis 183:1801-4|
|Mayanja-Kizza, H; Johnson, J L; Hirsch, C S et al. (2001) Macrophage-activating cytokines in human immununodeficiency virus type 1-infected and -uninfected patients with pulmonary tuberculosis. J Infect Dis 183:1805-9|
|Aung, H; McKenna, S M; Ketoff, N R et al. (2001) Dysregulation of beta-chemokines in the lungs of HIV-1-infected patients. J Acquir Immune Defic Syndr 26:305-14|
Showing the most recent 10 out of 21 publications